On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.
Save 20% on Press Releases and More with NNW Prime! Click to View Details
ThursdayMay 11, 2017 11:07 am

NetworkNewsBreaks – India Globalization Capital, Inc. (NYSE: IGC) Poised to Become Phytocannabinoid Pharmaceuticals Leader

At its recent 70th annual meeting, the American Epilepsy Society (AES) highlighted a study focusing on the potential of cannabidiol (CBD) to treat the frequency and severity of seizures in children who have drug-resistant epilepsies. India Globalization Capital (NYSE MKT: IGC), an innovator in developing cannabis-based combination therapies to treat pain and other conditions, is currently applying the revolutionary seizure-treating potential of CBD to another population: domestic pets, and the company is addressing the 5 percent of dogs and just over 2 percent of cats in the United States that experience seizures. “Cannabidiol is the most abundant non-psychoactive cannabinoid found…

Continue Reading

WednesdayMay 10, 2017 1:58 pm

NetworkNewsBreaks – ABcann Global Corporation (TSXV: ABCN) Extends Role of “Father of Marijuana Research” Raphael Mechoulam

In a news release issued early Tuesday, ABcann Global Corporation (TSXV: ABCN) announced that Raphael Mechoulam has agreed to extend his role as an advisor to the company. Aaron Keay, CEO and director of ABcann, spoke to the importance of this agreement in the news release. “Professor Mechoulam’s experience in medicinal cannabis is an invaluable resource for ABcann as we enter the most aggressive growth stage in the company’s history,” he stated. “The Company has invested heavily to build and extend its early leadership in advanced pharmaceutical-grade cannabis production. Professor Mechoulam’s advice, guidance, and unmatched expertise in the field has…

Continue Reading

WednesdayMay 10, 2017 12:51 pm

NetworkNewsBreaks – Top 10 Mid-day Percentage Gainers on May 10, 2017

Here is a list of stocks shaking up the markets today, with particular focus on NASDAQ and OTC small caps. The top gainers based on percentage: MNKD 49.11% – News: Hosting earnings call at 5 p.m. ET MTBC 34.49% – News: Posts Q1 2017 results ARGS 21.71% – News: Provides update on the ADAPT trial BXNG 19.94% – News: Gifts cost of unique wedding at Denver church PESI 12.50% – News: Posts Q1 2017 results ECIA 12.50% – News: Posts Q4 fiscal 2017 results MIHI 9.50% – News: Issues shareholder update SORL 8.21% – News: Releasing Q1 2017 results May…

Continue Reading

WednesdayMay 10, 2017 12:49 pm

NetworkNewsBreaks – Aegis Capital Reiterates ‘Buy’ Rating, $11 PT on Recro Pharma, Inc. (NASDAQ: REPH)

Aegis Capital has issued a ‘Buy’ rating and price target of $11 on Recro Pharma (NASDAQ: REPH) following the company’s recent report of positive top-line results from its phase 3 safety study evaluating intravenous (IV) meloxicam following major surgery. The analyst noted that the final clinical requirement was met for the IV Meloxicam NDA, and the company is on track to file in the third quarter of 2017. Shares of Recro Pharma are currently trading at $7.57 with a 52-week range of $0.59-$12.50. For more information, visit www.recropharma.com About Recro Pharma, Inc. Recro is a specialty pharmaceutical company that operates…

Continue Reading

WednesdayMay 10, 2017 12:47 pm

NetworkNewsBreaks – Aegis Capital Reiterates ‘Buy’ Rating on Axsome Therapeutics, Inc. (NASDAQ: AXSM)

Aegis Capital has reiterated a ‘Buy’ rating and price target of $20 on Axsome Therapeutics (NASDAQ: AXSM) after the company reported financial results for the quarter ended March 31, 2017. The analyst noted that although Axsome reported revenue in-line with consensus estimates, the focus remains on upcoming catalysts such as the company’s ongoing clinical trials. Since February 2017, the company’s AXS-05 has received fast track designation from the FDA for the treatment of Alzheimer’s disease (AD) agitation and treatment resistant depression (TRD). Topline data from the TRD treatment study is expected in the first quarter of 2018. Additionally, Axsome is…

Continue Reading

WednesdayMay 10, 2017 12:44 pm

NetworkNewsBreaks – Proteon Therapeutics, Inc.’s (NASDAQ: PRTO) Vonapanitase Receives Breakthrough Therapy Designation by FDA; Shares Soar

Proteon Therapeutics (NASDAQ: PRTO) shares are up 35% this morning on news that vonapanitase has received Breakthrough Therapy designation from the FDA. The investigational treatment received the designation for increasing arteriovenous fistula secondary patency (i.e., survival of the fistula without abandonment) and use for hemodialysis in patients on or expected to initiate hemodialysis. Secondary patency and fistula use for hemodialysis are also the co-primary endpoints of the company’s ongoing pivotal phase 3 clinical trial, PATENCY-2. Enrollment in the trial is anticipated to be complete in the first quarter of 2018, and the company expects top-line data in the first quarter…

Continue Reading

WednesdayMay 10, 2017 10:46 am

NetworkNewsBreaks – Net Element, Inc. (NASDAQ: NETE) Launches Enhanced Aptito System alongside Nationwide Sales Campaign

Mobile payment technology company Net Element, Inc. (NASDAQ: NETE) today announced significant enhancements to its cloud-based Aptito point-of-sale and mobile point-of-sale system. Some of the new features integrated into the platform as part of this update include enhanced options for reservations, bartending, reporting and kiosks; advanced printing, inventory and monitoring systems; the ability to import/export menus; the option to modify partially paid orders; and key enhancement pertaining to gift cards, inventory and system security. “A vast majority of restaurants are still using old legacy POS systems that fail to accommodate digital changes and consumer demands for convenience, speed, accuracy and…

Continue Reading

WednesdayMay 10, 2017 9:39 am

NetworkNewsBreaks – InMed Pharmaceuticals (IMLFF) Announces Filing of Provisional Patent for INM-085

Pre-clinical stage biopharmaceutical company InMed Pharmaceuticals, Inc. (OTCQB: IMLFF) (CSE: IN) this morning announced the filing of a provisional patent application in the United States for INM-085 as a cannabinoid-based topical therapy for glaucoma. The company notes that this move marks an important step toward providing intellectual and commercial protection for INM-085. If approved, INM-085 could address an expansive global market that’s currently valued in excess of $5 billion. Per this morning’s update, glaucoma is currently the second-leading cause of blindness, driven by risk factors such as increased pressure in the eye, a family history of the condition, migraines, high…

Continue Reading

WednesdayMay 10, 2017 9:23 am

NetworkNewsBreaks – SRAX (NASDAQ: SRAX) Introduces New Branding Initiative

Internet advertising company SRAX (NASDAQ: SRAX), formerly Social Reality, this morning announced its new brand, which aims to better reflect the company’s family of SRAX-branded products. “While our roots are in social media, the platform and tools we provide today automate brands' campaigns across all digital channels,” Chris Miglino, CEO and chairman of SRAX, stated in the news release. “Our new SRAX branding demonstrates the goal of our platform and tools to deliver a digital competitive advantage for brands to surpass the marketing challenges they face.” The company’s current products include SRAX Platform, a custom digital media management platform driven…

Continue Reading

TuesdayMay 09, 2017 1:14 pm

NetworkNewsBreaks – Top 10 Mid-day Percentage Gainers on May 9, 2017

Here is a list of stocks shaking up the markets today, with particular focus on NASDAQ and OTC small caps. The top gainers based on percentage: SPLY 37.50% – News: Enters LOI with Spot and Pay, Inc. AVCO 26.67% – News: Acquires Freehold Executive Center in NJ CGEN 12.14% – News: Posts Q1 2017 financial results SMSI 11.82% – News: FOTA software selected by Kona S DTGI 11.11% – News: Enters definitive agreement to acquire T3 Communications, Inc. SGLB 9.77% – News: Exhibiting new PrintRite3D® INSPECT™ V.2.0 at Rapid 2017 ARLZ 9.08% – News: Posts Q1 2017 financial results CAMT…

Continue Reading

Contact us: 212.418.1217